The Latest Cardiac and Vascular News
INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to placebo in the SOLOIST-WHF […]
First-of-its-Kind Low Profile, High Continuous Flow Device May Reduce Risk of Vascular Complications Associated with Current Devices Phoenix, AZ – Findings from the first-in-human trial of a novel percutaneous ventricular assist device (pVAD) were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific […]
MONITOR-HF is the third randomized, controlled trial globally to show a significant health benefit for indicated heart failure patients CardioMEMS is a paperclip-sized sensor that can remotely flag to a patient’s clinical team the early warning signs of worsening heart failure ABBOTT PARK, Ill., May 24, 2023 /PRNewswire/ — New data presented […]
DURHAM, N.C., May 24, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary conditions, today announced results from studies of AER-901 (inhaled imatinib) that support progression into a Phase 2 clinical trial in both pulmonary […]
Artivion to Receive $18.75 Million Milestone Payment Under Previously Announced Agreement Artivion to Begin Supplying Product to Baxter Under Transitional Manufacturing and Supply Agreement ATLANTA, May 23, 2023 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) granted premarket […]
First FGF21 analog to enter Phase 3 development SAN FRANCISCO, May 23, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the initiation of ENTRUST, a Phase 3 […]
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeting for the CardiAMP Cell Therapy Trial for Heart Failure is scheduled to take place […]
– 44-48% Mean Reductions in LDL-C Achieved on Top of Continued Standard of Care – Phase 3 Planning is Ongoing PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression […]
FIRST-EVER PHASE III RANDOMIZED CONTROLLED TRIAL OF ATRIAL SHUNT THERAPY SHOWS CONTINUED PROMISE TEWKSBURY, Mass., May 22, 2023 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced two-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the […]
The CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally. Results of initial programs in São Paulo, Dakar and Ulaanbaatar show the cost-effective approach averted up to 13% of strokes and 12% […]
